Sarepta

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Retrieved on: 
Sunday, November 5, 2023
Sarepta, FDA, OTP, Food, Prior, May 29, News, SRPT, Pomerantz, LLP, Duchenne, Duchenne muscular dystrophy, DMD, BLA, Pharmaceutical industry, Cryptocurrency, Therapy

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

Retrieved on: 
Thursday, November 2, 2023
Titan, Sarepta, Sarepta Therapeutics, I-Space (Chinese company), Advertising, SRPT

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=20094 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Sarepta Therapeutics to Present at the UBS Biopharma Conference

Retrieved on: 
Thursday, November 2, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Sarepta, Fontainebleau Miami Beach, Conference, Therapy, Event, SRPT, Rare, Software, Pharmaceutical industry, Online shopping, Vaccine

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 9:00 a.m. E.T.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the UBS Biopharma Conference on Thursday, Nov. 9, 2023 at 9:00 a.m. E.T.
  • The fireside chat will be held at the Fontainebleau Miami Beach in Miami Beach, Fla.
  • The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days.
  • Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, October 31, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Sarepta, Compensated emancipation, Sarepta Therapeutics, Therapy, SRPT, Employment, RSU, Rare, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in October 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in October 2023.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 10,675 shares of Sarepta's common stock, and in the aggregate 6,050 restricted stock units (“RSUs”).
  • The options have an exercise price of $67.31 per share, which is equal to the closing price of Sarepta's common stock on October 31, 2023 (the “Grant Date”).

ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT

Retrieved on: 
Tuesday, October 31, 2023
Class Action Lawsuit, Professional Services, Legal, Titan, Sarepta, Sarepta Therapeutics, I-Space (Chinese company), Advertising, SRPT

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Genetics, Health, Clinical Trials, Sarepta, Șaeș, PIN, UC, Vomiting, Rehabilitation, History, Nausea, SAE, Sarepta Therapeutics, Interest, Disease, Clinical trial, Roche, DMD, Physical medicine and rehabilitation, Therapy, Patient, Appetite, Pharmaceutical industry, Fever, Duchenne

Full results from EMBARK will be shared at future medical meetings and publication will be pursued in a medical journal.

Key Points: 
  • Full results from EMBARK will be shared at future medical meetings and publication will be pursued in a medical journal.
  • “The consistency of the positive effect across all timed function tests and age groups provides evidence of a meaningful treatment effect.
  • On October 30, 2023, at 4:30 p.m. Eastern time, Sarepta will host a conference call and webcast to discuss these results.
  • Sarepta is responsible for regulatory approval and commercialization of ELEVIDYS in the U.S., as well as manufacturing.

Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, October 25, 2023
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Sarepta, Interest, Therapy, SRPT, PIN, Rare, Pharmaceutical industry, Online shopping

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 1, 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 1, 2023.
  • Subsequently, at 4:30 p.m.
  • E.T., the Company will host a conference call to discuss its third quarter 2023 financial results.
  • Interested parties participating by phone will need to register using this online form .

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 29, 2023
Biotechnology, Pharmaceutical, Genetics, Health, SRPT, Sarepta, Sarepta Therapeutics, Employment, Rare, Therapy, RSU, Compensated emancipation, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in September 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in September 2023.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 16,575 shares of Sarepta's common stock, and in the aggregate 8,575 restricted stock units (“RSUs”).
  • The options have an exercise price of $121.22 per share, which is equal to the closing price of Sarepta's common stock on September 29, 2023 (the “Grant Date”).

Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 5, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SRPT, Morgan, Sarepta, Sheraton New York Times Square Hotel, Rare, Therapy, Conference, Event, Software, Pharmaceutical industry, Online shopping, Cryptocurrency

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T.
  • The fireside chat will be held at the Sheraton New York in New York, NY.
  • The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days.
  • Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Retrieved on: 
Tuesday, September 5, 2023
Treasury, Amgen, Common stock, Employment, University, Eteplirsen, Therapy, General counsel, International, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, IBD, Sarepta, Cornell Law School, Arthur Andersen, Record, Corporate law, MBA, Dartmouth College, Inflammatory bowel disease, Sarepta Therapeutics, Rope, Comparative law, Acquisition, Doctor of Philosophy, Patient, Corporation, CPA, Sanofi, Security (finance), TL1A, BA, Pharmaceutical industry, Management

WALTHAM, Mass., Sept. 5, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary. Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team. Aeglea also announced that Jonathan Alspaugh, Aeglea's current President and Chief Financial Officer, is expected to transition into a strategic advisory consulting role through December 31, 2023.

Key Points: 
  • Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team.
  • "Scott and Heidy both bring extraordinary expertise and leadership skills through their proven track records at public biopharma companies with both investigational and commercialized products," said Cameron Turtle, DPhil.
  • On behalf of the management team and Board of Directors, I would also like to thank Jonathan for his steadfast commitment to the company."
  • Mr. Burrows is a veteran of the biopharma industry with more than two decades of diverse experience and a proven track-record in biopharmaceutical finance leadership roles spanning multiple public companies.